Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2012
06/21/2012WO2012080446A1 Benzimidazole respiratory syncytial virus inhibitors
06/21/2012WO2012080408A1 Pharmaceutical composition for oral administration intended to prevent misuse
06/21/2012WO2012080399A1 Zolpidem-based orodispersible pharmaceutical tablet
06/21/2012WO2012080371A1 New thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
06/21/2012WO2012080365A1 Transdermal therapeutic system for administering an active substance
06/21/2012WO2012080362A1 Preparation comprising insulin, nicotinamide and an amino acid
06/21/2012WO2012080329A1 Formulations of n-(3,5-dichloropyridin-4-yl)-[1-(4-fluorobenzyl)-7-azaindol-3-yl)]glyoxylic acid amide
06/21/2012WO2012080284A2 Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
06/21/2012WO2012080273A1 N- acetyl - l - cysteine for treatment of polycystic ovary syndrome
06/21/2012WO2012080271A1 Dimeric iap inhibitors
06/21/2012WO2012080260A1 Dimeric iap inhibitors
06/21/2012WO2012080240A1 Cyclohexane compounds and their use as antibiotics
06/21/2012WO2012080237A1 Substituted pyrimido[1,2-b]indazoles and their use as modulators of the pi3k/akt pathway
06/21/2012WO2012080236A1 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
06/21/2012WO2012080234A1 Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
06/21/2012WO2012080232A1 2-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
06/21/2012WO2012080230A1 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
06/21/2012WO2012080229A1 Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders
06/21/2012WO2012080228A1 6-thio-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
06/21/2012WO2012080221A1 New compounds for the treatment of neurodegenerative diseases
06/21/2012WO2012080220A1 Novel compounds for the treatment of neurodegenerative diseases
06/21/2012WO2012080216A1 Orally disintegrating tablet having a taste masking effect
06/21/2012WO2012080186A1 Composition and use of a fermented olive leaf product for the treatment of nail and skin infections.
06/21/2012WO2012080151A1 Combination therapy comprising vemurafenib and an interferon for use in the treatment of cancer
06/21/2012WO2012080149A1 Novel benzofurane compounds
06/21/2012WO2012080144A1 Oxime compounds as hdl-cholesterol raising agents
06/21/2012WO2012080050A1 Solid forms of a phenoxybenzenesulfonyl compound
06/21/2012WO2012079721A1 Terpenoid spiro ketal compounds with lxr agonists activity, their use and formulations with them
06/21/2012WO2012079578A1 Selective killing of cancer cells
06/21/2012WO2012079576A1 Methods and models for predicting dosage of a drug and/or response in an individual
06/21/2012WO2012079532A1 Dicoumarol-like compounds and preparation method and use thereof
06/21/2012WO2012079497A1 Bromfenac organic salts and preparation method, composition and use thereof
06/21/2012WO2012079289A1 Amorphous powder and polymorph of carbapenem derivative, preparation method therefor and use thereof
06/21/2012WO2012079279A1 Pregnane glycoside compounds containing orthoester groups and use thereof
06/21/2012WO2012079232A1 Compounds used for treating cancer and the use thereof
06/21/2012WO2012079203A1 Puerarin hydrates, preparation methods and uses thereof
06/21/2012WO2012079164A1 Activators of cylindrical proteases
06/21/2012WO2012079154A1 Selective estrogen receptor modulators
06/21/2012WO2012079146A1 Nitric oxide amino acid esters for improving vascular circulation, and prophylaxis or treatment of a condition associated with impaired blood circulation
06/21/2012WO2012079128A1 Thiosemicarbazone compounds and use in the treatment of cancer
06/21/2012WO2012079118A1 Gastric and colonic formulations and methods for making and using them
06/21/2012WO2012079115A1 Immunostimulatory oligonucleotides
06/21/2012WO2012070062A3 Novel polymorph of nilotinib hydrochloride
06/21/2012WO2012058531A3 Modulation of response regulators by imidazole derivatives
06/21/2012WO2012058462A3 Combination therapy for the treatment of cancer
06/21/2012WO2012058127A3 Novel compounds that are erk inhibitors
06/21/2012WO2012056471A3 Preparing dexibuprofen ready-to-compress granules
06/21/2012WO2012054807A3 Vaccines comprising bisphosphonate and methods of use thereof
06/21/2012WO2012054739A3 Structure-guided identification of binding interactions of human laminin receptor precursor with laminin and identification of compounds that affect binding
06/21/2012WO2012053768A3 Aryloxyphenoxyacetyl-based compound having hif-1 inhibition activity, preparation method thereof and pharmaceutical composition containing the same as an active ingredient
06/21/2012WO2012051601A3 Heteroarylthio compounds
06/21/2012WO2012051213A3 Therapeutic 5,6,5-tricyclic analogs
06/21/2012WO2012051107A3 Niacin formulations and methods with reduced flushing side-effect
06/21/2012WO2012050918A3 Tricyclic fused ring inhibitors of hepatitis c
06/21/2012WO2012050907A3 Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes
06/21/2012WO2012050380A3 Novel pyridyl benzoxazine derivatives, pharmaceutical composition comprising the same, and use thereof
06/21/2012WO2012048181A4 Novel substituted quinoline compounds as s-nitrosoglutathione reductase inhibitors
06/21/2012WO2012047956A3 Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
06/21/2012WO2012047852A3 Compositions and methods for modulating immunodeficiency virus transcription
06/21/2012WO2012047733A3 Treatment of acne by conditioned media
06/21/2012WO2012044090A3 Novel aminoquinazoline compound having a protein-kinase inhibiting action
06/21/2012WO2012040754A3 Novel thiazolamine derivates as differentiation accelerators
06/21/2012WO2012040170A3 Compositions and methods for treating tuberculosis
06/21/2012WO2012034038A3 Dual inhibitors of farnesyltransferase and geranylgeranyltransferase i
06/21/2012WO2012031125A3 Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine
06/21/2012WO2012031124A3 Drug formulations using water soluble antioxidants
06/21/2012WO2012031090A9 Small molecule inhibitors of ebola and lassa fever viruses and methods of use
06/21/2012WO2012031045A3 Phosphonate ester derivatives and methods of synthesis thereof
06/21/2012WO2012030993A3 Skin compositions and methods of use thereof
06/21/2012WO2012027712A3 Potent and selective inhibitors of hepatitis c virus
06/21/2012WO2012027555A3 Glycated cd59 peptides, their preparation, and uses thereof
06/21/2012WO2012027514A3 Compositions and methods for cardiac therapy
06/21/2012WO2012025187A3 Furopyridine derivatives
06/21/2012WO2012020989A9 Pharmaceutical or cosmetic composition containing nicotinic acid adenine dinucleotide phosphate or derivative thereof
06/21/2012WO2012012498A3 Use of trp channel agonists to treat infections
06/21/2012WO2012002741A3 Process for the preparation of hmg-coa reductase inhibitors and intermediates thereof
06/21/2012WO2011163600A3 Tacrolimus compositions for aerosol administration
06/21/2012WO2011161223A3 Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts
06/21/2012WO2011161123A3 Multilayer pharmaceutical tablet comprising telmisartan and a diuretic
06/21/2012WO2011145035A8 Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
06/21/2012WO2011135314A3 Pharmaceutical powder compositions
06/21/2012WO2011090741A9 TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63
06/21/2012WO2011084456A9 Ppar-sparing thiazolidinediones and combinations for the treatment of diabetes mellitus and other metabolic diseases
06/21/2012WO2011051540A9 Androgen receptor modulating compounds
06/21/2012WO2011019995A3 Synthesis and identification of novel rsk-specific inhibitors
06/21/2012WO2010075517A3 Nucleoside phosphoramidate prodrugs
06/21/2012WO2009023653A3 Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators
06/21/2012US20120159661 T-Bet Compositions and Methods of Use Thereof
06/21/2012US20120159657 Compositions and Methods for Inhibiting Expression of RRM2 Genes
06/21/2012US20120159655 Methods using axl as a biomarker of epithelial-to-mesenchymal transition
06/21/2012US20120157937 Transdermal therapeutic system provided with improved long-term carrying comfort
06/21/2012US20120157917 High pressure delivery system and method for treating pelvic disorder using large molecule therapeutics
06/21/2012US20120157685 Intermediate release nicotinic acid compositions for treating hyperlipidemia which exhibit an in vivo stair-stepped absorption curve
06/21/2012US20120157549 Methods of preventing, treating and diagnosing disorders of protein aggregation
06/21/2012US20120157547 Compositions and applications of carotenoids of improved absorption and bioavailability
06/21/2012US20120157546 Compositions Containing Aromatic Aldehydes and Their Use in Treatments
06/21/2012US20120157545 Methods for treating skin disorders with topical nitrogen mustard compositions
06/21/2012US20120157544 Process for the Preparation of O-Desmethyl Venlafaxine and Intermediate for Use Therein
06/21/2012US20120157543 Preparation of (r,r)-fenoterol and (r,r)-or (r,s)-fenoterol analogues and their use in treating congestive heart failure
06/21/2012US20120157542 Method to assess prognosis and to predict therapeutic success in cancer by determining hormone receptor expression levels
1 ... 1172 1173 1174 1175 1176 1177 1178 1179 1180 1181 1182 1183 1184 1185 1186 1187 1188 1189 1190 1191 1192 ... 7860